RE:Range of CR at 450 day mark N0taP00p ...
You forgot to mention that we had 11 new patients that had been enrolled and treated but that had not been evaluated yet @90-days. We'll see how many of these 11 enter the pool of evaluable patients at the next update.
So those that are tired of havng "no news" forgot to consider this in their whining. By chance, TLT management knows what's best for shareholders and that cutting corners is not in our best interest. In this case, having 70% of those 11 having a CR @90-days could get us more visibility and one of capital importance, ahead of AUA conference.
70% is the efficacy % that we gt so far if we remove 10 of the 12 undertreated. So I'm using this % for the 11 not-yet-evaluated to better assess where we could land @90-days. I recently posted on this. TR @90-days could reach 69% (37/54). CR@90-days could reach 57%. The wait is worth it. Nothing to be tired about. On the contrary, rather energizing if these %s become reality. All this, with 12 undertreated! Imagine if the FDA decides to analyze the results of only optimized patients as a sub-group!